Get the Stockscreener App
58.96
4.04%
2.29
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Bristol Myers Squibb Co stock is traded at $58.96, with a volume of 5.59M.
It is up +4.04% in the last 24 hours and down -8.02% over the past month.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
See More
Previous Close:
$56.67
Open:
$56.81
24h Volume:
5.59M
Relative Volume:
0.40
Market Cap:
$120.44B
Revenue:
$48.48B
Net Income/Loss:
$7.27B
P/E Ratio:
16.55
EPS:
3.5626
Net Cash Flow:
$11.91B
1W Performance:
-1.24%
1M Performance:
-8.02%
6M Performance:
+1.52%
1Y Performance:
+34.61%
1-Day Range:
$56.58
$58.96
1-Week Range:
$56.15
$60.68
52-Week Range:
$42.52
$68.64
Bristol Myers Squibb Co Stock (BMY) Company Profile
Name
Bristol Myers Squibb Co
Sector
Industry
Phone
(609) 252-4621
Address
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.96 | 120.44B | 48.48B | 7.27B | 11.91B | 3.5626 |
LLY
Lilly Eli Co
|
1,211.89 | 1.08T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
253.18 | 610.14B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
285.09 | 503.79B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.53 | 363.98B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
146.71 | 278.85B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-05-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Aug-05-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Upgrade | UBS | Neutral → Buy |
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-25 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Perform |
| Aug-05-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Apr-22-25 | Initiated | Piper Sandler | Overweight |
| Dec-16-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-13-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Nov-12-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-25-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jul-29-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-11-24 | Downgrade | Societe Generale | Buy → Hold |
| Feb-06-24 | Downgrade | Redburn Atlantic | Buy → Neutral |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-15-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Nov-02-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Oct-27-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Oct-27-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Oct-27-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jul-10-23 | Initiated | SVB Securities | Market Perform |
| Jun-28-23 | Initiated | Daiwa Securities | Outperform |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Jan-17-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-18-22 | Initiated | Credit Suisse | Neutral |
| Oct-10-22 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-14-22 | Downgrade | Berenberg | Buy → Hold |
| Jun-03-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Underweight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Nov-01-21 | Downgrade | Argus | Buy → Hold |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-30-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-13-21 | Upgrade | Truist | Hold → Buy |
| Nov-16-20 | Upgrade | Societe Generale | Hold → Buy |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Nov-06-20 | Downgrade | Gabelli & Co | Buy → Hold |
| Oct-19-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Jul-28-20 | Initiated | Raymond James | Outperform |
| Apr-02-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Jan-06-20 | Resumed | Citigroup | Buy |
| Dec-13-19 | Upgrade | Argus | Hold → Buy |
| Nov-22-19 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| Aug-14-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| May-28-19 | Initiated | Goldman | Buy |
| May-20-19 | Downgrade | Argus | Buy → Hold |
| May-03-19 | Upgrade | Barclays | Equal Weight → Overweight |
| May-03-19 | Resumed | JP Morgan | Overweight |
| Jan-15-19 | Upgrade | Societe Generale | Sell → Buy |
| Oct-22-18 | Downgrade | Citigroup | Buy → Neutral |
View All
Bristol Myers Squibb Co Stock (BMY) Latest News
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
BlackLine Honors Global Enterprise Leaders Transforming Financial Operations - GlobeNewswire Inc.
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today - Zacks Investment Research
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.35% on Oct 12: What Signal Does It Send? - TradingKey
Bristol Myers Squibb (BMY) Reports Positive Phase 3 Trial Results for Admilparant in IPF - GuruFocus
13 New 4-Star Stocks This Week - Morningstar
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? - TradingView
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock? - Zacks Investment Research
Bristol Myers Squibb stock costs EUR 51.10 at USD 116.7 billion value - ad-hoc-news.de
Bristol Myers’ Drugs Succeed in Treating Lung Disease, Cancer - Bloomberg.com
bristol myers squibb ryz101 phase 3 trial meets progression free survival endpoint - grafa.com
Bristol Myers radiopharma cancer drug slows rare tumor progression in study - Reuters
Bristol Myers Squibb (BMY) Shares Rise After Positive Phase 3 Tr - GuruFocus
Why Is Bristol Myers Squibb Stock Gaining Monday? - Benzinga
On the 12th Edition of Global Patient Week Bristol Myers Squibb and Saudi Schizophrenia Association 'Ehtiwaa' Collaborate to Support People Living with Schizophrenia Through the 'Small Wins' Initiative - PR Newswire UK
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Stocks Are Expensive and Investors Are Getting Scared. Warren Buffett's 13-Word Rule Has Specific Advice for Both Conditions. - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
20,370 Bristol Myers Squibb Company $BMY Shares Bought by Apella Capital LLC - MarketBeat
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn - MarketBeat
Bristol Myers Squibb Co. Advanced Charts | BMY - Barron's
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
230,245 Bristol Myers Squibb Company $BMY Shares Sold by Artemis Investment Management LLP - MarketBeat
Bristol Myers Squibb’s Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51% - Benzinga
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results - Zacks Investment Research
AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer - Zacks Investment Research
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors - GlobeNewswire Inc.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now? - Zacks Investment Research
2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) - The Motley Fool
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward? - Zacks Investment Research
Can Redwire's Microgravity Pharma Work Create New Revenue Streams? - Zacks Investment Research
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb to $41 From $40 - Yahoo Finance
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock - Zacks Investment Research
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Bristol-Myers Squibb: Patent Cliff Is Still A Problem (NYSE:BMY) - Seeking Alpha
Zacks.com featured highlights Dollar General, Bristol-Myers Squibb and Equinor ASA - Zacks Investment Research
Bristol-Myers Squibb Co (BMY) Shares Fall 3.8% -- GF Value Says Still Overvalued - GuruFocus
Bristol-Myers Squibb Co: Prelim Total Acquire - Moomoo
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.56% on Oct 5: What Investors Need To Know - TradingKey
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb (BMY) withholds 2,332 shares for taxes as Cari Gallman's stock award vests. - Stock Titan
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Investing.com
Bristol-Myers Squibb shares slide as Leerink Partners downgrades on pipeline doubt - Yahoo Finance
Are Investors Undervaluing Bristol Myers Squibb (BMY) Right Now? - Zacks Investment Research
Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement - Yahoo Finance
Bristol Myers Squibb Co. Research & Ratings | BMY - Barron's
Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns - ChartMill
Bristol Myers Squibb Co Stock (BMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bristol Myers Squibb Co Stock (BMY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Sep 09 '26 |
Sale |
64.57 |
6,249 |
403,498 |
18,748 |
| Massacesi Cristian | Officer |
Sep 09 '26 |
Proposed Sale |
64.57 |
6,249 |
403,498 |
0 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Sep 01 '26 |
Option Exercise |
66.92 |
1,236 |
82,713 |
13,317 |
| Holzer Phil M | Officer |
Aug 25 '26 |
Proposed Sale |
67.50 |
500 |
33,750 |
0 |
| Holzer Phil M | SVP and Controller |
Aug 25 '26 |
Sale |
67.50 |
500 |
33,750 |
16,862 |
| Gallman Cari | EVP, General Counsel |
Aug 01 '26 |
Option Exercise |
0.00 |
1,061 |
0 |
14,192 |
| Massacesi Cristian | EVP,Chief Med Offr,Head of Dev |
Aug 01 '26 |
Option Exercise |
0.00 |
51,172 |
0 |
51,172 |
| Haller Julia A | Director |
Jun 15 '26 |
Option Exercise |
53.76 |
20,460 |
1,099,930 |
34,079 |
| Short Bartie Wendy | EVP, Corporate Affairs |
Jun 03 '26 |
Option Exercise |
0.00 |
8,040 |
0 |
15,957 |
| Lenkowsky Adam | EVP, Chief Commercial Officer |
May 01 '26 |
Option Exercise |
0.00 |
1,373 |
0 |
20,508 |
3.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):